Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Using the expression profile of peripheral blood to investigate regulatory pathways in schizophrenia

ABSTRACT: Schizophrenia is best considered a “two-hit” disease, with a neurodevelopment impairment followed by an additional process in early adulthood. Both are regulated by hormonal (like thyroid and retinols) and signal transduction pathways (like WNT), which in turn have been previously identified in post-mortem brain studies of schizophrenic individuals. While brain studies are fitted for pathology assessment, there are not suitable for searches of a “diagnostic signature” of schizophrenia. In contrast, peripheral blood is easily accessible, and can be used for the study of disease pathways and potentially diagnosis markers. Blood from twenty eight males with DSM-IV schizophrenia under three drug regimens (clozapine, risperidone or haloperidol), and from 10 healthy controls was studied in a microarray platform with 1364 genes belonging to hormonal and signal transduction pathways. Seven genes were differentially expressed between controls and patients with different treatments, and 28 between healthy controls and specific treatments, with four (CTNNA1, GSTM3, HOXA-13 and KRT18) altered in all analyses. While none of these genes has been previously reported in schizophrenia brain studies, many belong to pathways altered in schizophrenia, belonging to chromosomal loci linked to the disease, which warrants additional replication studies to be performed in larger samples.

ORGANISM(S): Homo sapiens

PROVIDER: GSE19112 | GEO | 2012/06/22

SECONDARY ACCESSION(S): PRJNA120465

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions (striatum LNDBB).

Project description:Genetic association studies provide evidence for a substantial polygenic component to schizophrenia, although the neurobiological mechanisms underlying the disorder remain largely undefined. Building on recent studies supporting a role for developmentally regulated epigenetic variation in the molecular etiology of schizophrenia, this study aimed to identify epigenetic variation associated with both a diagnosis of schizophrenia and elevated polygenic risk burden for the disease across multiple brain regions. Genome-wide DNA methylation was quantified in 262 post-mortem brain samples, representing tissue from four brain regions (prefrontal cortex, striatum, hippocampus and cerebellum) from 41 schizophrenia patients and 47 controls. We identified multiple disease-associated and polygenic risk score-associated differentially methylated positions and regions, many residing in the vicinity of genes previously implicated in schizophrenia including NCAM1, SYNPO, GBP4, PRDM9, GADD45B and DISC1. Our study represents the first analysis of epigenetic variation associated with schizophrenia across multiple brain regions and highlights the utility of polygenic risk scores for identifying molecular pathways associated with etiological variation in complex disease.

2016-11-10 | GSE89706 | GEO

Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions (hippocampus LNDBB).

2016-11-10 | GSE89703 | GEO

Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions (striatum DBCBB).

2016-11-10 | GSE89705 | GEO

Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions (cerebellum DBCBB).

2016-11-10 | GSE89702 | GEO

Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia.

Project description:Background: Schizophrenia is a severe neuropsychiatric disorder that is hypothesized to result from disturbances in early brain development, and there is mounting evidence to support a role for developmentally-regulated epigenetic variation in the molecular etiology of the disorder. Here, we describe a systematic study of schizophrenia-associated methylomic variation in the adult brain and its relationship to changes in DNA methylation across human fetal brain development. Results: We profile methylomic variation in matched prefrontal cortex and cerebellum brain tissue from schizophrenia patients and controls, identifying disease-associated differential DNA methylation at multiple loci, particularly in the prefrontal cortex, and confirming these differences in an independent set of adult brain samples. Our data reveal discrete modules of co-methylated loci associated with schizophrenia that are enriched for genes involved in neurodevelopmental processes and include loci implicated by genetic studies of the disorder. Methylomic data from human fetal cortex samples, spanning 23 to 184 days post-conception, indicates that disease-associated differentially methylated positions are significantly enriched for loci at which DNA methylation is dynamically altered during human fetal brain development. Conclusions: Our data support the hypothesis that schizophrenia has an important early neurodevelopmental component, and suggest that epigenetic mechanisms may mediate these effects. 33 post-mortem brain (prefrontal cortex) samples (18 schizophrenia cases and 15 controls) were obtained from Douglas Bell-Canada Brain Bank (DBCBB), Montreal, Canada. Bisulfite converted DNA from these samples were hybridised to the Illumina Infinium 450k Human Methylation Beadchip v1.0.

2014-09-13 | E-GEOD-61380 | biostudies-arrayexpress

Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients

Project description:Recent studies suggest that genetic and environmental factors do not account for all the schizophrenia risk and epigenetics also plays a role in disease susceptibility. DNA methylation is a heritable epigenetic modification that can regulate gene expression. Genome-Wide DNA methylation analysis was performed on post-mortem human brain tissue from 24 patients with schizophrenia and 24 unaffected controls. DNA methylation was assessed at over 485 000 CpG sites using the Illumina Infinium Human Methylation450 Bead Chip. After adjusting for age and post-mortem interval (PMI), 4 641 probes corresponding to 2 929 unique genes were found to be differentially methylated. Of those genes, 1 291 were located in a CpG island and 817 were in a promoter region. These include NOS1, AKT1, DTNBP1, DNMT1, PPP3CC and SOX10 which have previously been associated with schizophrenia. More than 100 of these genes overlap with a previous DNA methylation study of peripheral blood from schizophrenia patients in which 27 000 CpG sites were analysed. Unsupervised clustering analysis of the top 3 000 most variable probes revealed two distinct groups with significantly more people with schizophrenia in cluster one compared to controls (p = 1.74x10-4). The first cluster was composed of 88% of patients with schizophrenia and only 12% controls while the second cluster was composed of 27% of patients with schizophrenia and 73% controls. These results strongly suggest that differential DNA methylation is important in schizophrenia etiology and add support for the use of DNA methylation profiles as a future prognostic indicator of schizophrenia Genome-Wide DNA methylation analysis was performed on post-mortem human brain tissue from 24 patients with schizophrenia and 24 unaffected controls. DNA methylation was assessed at over 485 000 CpG sites using the Illumina Infinium Human Methylation450 Bead Chip.

2014-09-05 | E-GEOD-61107 | biostudies-arrayexpress

Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia.

Project description:Background: Schizophrenia is a severe neuropsychiatric disorder that is hypothesized to result from disturbances in early brain development, and there is mounting evidence to support a role for developmentally-regulated epigenetic variation in the molecular etiology of the disorder. Here, we describe a systematic study of schizophrenia-associated methylomic variation in the adult brain and its relationship to changes in DNA methylation across human fetal brain development. Results: We profile methylomic variation in matched prefrontal cortex and cerebellum brain tissue from schizophrenia patients and controls, identifying disease-associated differential DNA methylation at multiple loci, particularly in the prefrontal cortex, and confirming these differences in an independent set of adult brain samples. Our data reveal discrete modules of co-methylated loci associated with schizophrenia that are enriched for genes involved in neurodevelopmental processes and include loci implicated by genetic studies of the disorder. Methylomic data from human fetal cortex samples, spanning 23 to 184 days post-conception, indicates that disease-associated differentially methylated positions are significantly enriched for loci at which DNA methylation is dynamically altered during human fetal brain development. Conclusions: Our data support the hypothesis that schizophrenia has an important early neurodevelopmental component, and suggest that epigenetic mechanisms may mediate these effects. Prefrontal cortex (PFC) and cerebellum samples were obtained from 46 brains archived in the London Brain Bank for Neurodegenerative Disorders (LBBND). Of these 22 were schizophrenia cases, ands of the cases 12 were male.

2014-09-18 | E-GEOD-61431 | biostudies-arrayexpress

Gene Expression Profiles in BA46 of Subjects with Schizophrenia and Matched Controls

Project description:Results from clinical and imaging studies provide evidence for changes in schizophrenia with disease progression, however, the underlying molecular differences that may occur at different stages of illness have not been investigated. To test the hypothesis that the molecular basis for schizophrenia changes from early to chronic illness, we profiled genome-wide expression patterns in prefrontal cortex of schizophrenic subjects at different stages of illness, along with their age- and sex-matched controls. Results show that gene expression profiles change dramatically depending on the stage of illness, whereby the greatest number and magnitude of gene expression differences were detected in subjects with short-term illness (â?¤ 4 years from diagnosis). Comprehensive pathways analyses revealed that each defined stage of illness was associated with dysfunction in both distinct, as well as overlapping systems. Short-term illness was particularly associated with disruptions in gene transcription, metal ion binding, RNA processing and vesicle-mediated transport. In contrast, long-term illness was associated with inflammation, stimulus-response and immune functions. We validated expression differences of 12 transcripts associated with these various functions by real-time PCR analysis. While only four genes, SAMSN1, CDC42BPB, DSC2 and PTPRE, were consistently expressed across all groups, there was dysfunction in overlapping systems among all stages, including cellular signal transduction, lipid metabolism and protein localization. Our results demonstrate that the molecular basis for schizophrenia changes from early to chronic stages, providing evidence for a changing nature of schizophrenia with disease progression. N=30 subjects with schizophrenia and n=29 age- and sex-matched controls. Age range = 18-81 years

2010-04-12 | E-GEOD-21138 | biostudies-arrayexpress

Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia.

2014-09-18 | GSE61431 | GEO

Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia.

2014-09-13 | GSE61380 | GEO